Novartis Triple Combo Enerzair Gets EU OK For Asthma

Nudges Ahead Of GSK's Trelegy in Europe

 
• By Kevin Grogan

The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.

Darts
Trebles all round at Novartis with Enerzair approval • Source: Shutterstock

More from Respiratory

More from Therapy Areas